LuteolinAnti-inflammatory, antioxidant and free radical scavenger CAS# 491-70-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 491-70-3 | SDF | Download SDF |
PubChem ID | 5280445 | Appearance | Yellow powder |
Formula | C15H10O6 | M.Wt | 286.2 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Synonyms | 3',4',5,7-Tetrahydroxyflavone | ||
Solubility | DMSO : ≥ 100 mg/mL (349.36 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | ||
SMILES | C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O | ||
Standard InChIKey | IQPNAANSBPBGFQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Luteolin is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Ki of 15.0 μM, 6.4 μM, 13.9 μM, 11.1 μM and 9.5 μM, respectively. Luteolin has anti-oxidant, anti-inflammation, anti-allergy anti-myocardial ischemia-reperfusion injury, and anticancer, has been used in Chinese traditional medicine for treating various diseases such as hypertension, inflammatory disorders, and cancer. Luteolin inhibits NF-κB, and inhibits interleukin (IL)-1β function induction of the inflammation biomarker cyclooxygenase (COX)-2. |
Targets | IL Receptor | COX | NF-kB | p65 | Akt | ERK | JNK | ROS | NADPH-oxidase | AP-1 | HIF | TNF-α | VEGFR | STAT | MMP(e.g.TIMP) | FAK | Bcl-2/Bax | PI3K | PDE |
In vitro | Biphasic effects of luteolin on interleukin-1β-induced cyclooxygenase-2 expression in glioblastoma cells.[Pubmed: 25409926]Biochim Biophys Acta. 2015 Jan;1853(1):126-35.Success in developing therapeutic approaches to target brain tumor-associated inflammation in patients has been limited. Given that the inflammatory microenvironment is a hallmark signature of solid tumor development, anti-inflammatory targeting strategies have been envisioned as preventing glioblastoma initiation or progression.
Consumption of foods from plant origin is associated with reduced risk of developing cancers, a chemopreventive effect that is, in part, attributed to their high content of phytochemicals with potent anti-inflammatory properties.
Luteolin inhibits Cr(VI)-induced malignant cell transformation of human lung epithelial cells by targeting ROS mediated multiple cell signaling pathways.[Pubmed: 25448439]Toxicol Appl Pharmacol. 2014 Dec 1;281(2):230-41.Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated with the incidence of lung cancer. Inhibition of metal induced carcinogenesis by a dietary antioxidant is a novel approach.
Luteolin, a natural dietary flavonoid found in fruits and vegetables, possesses potent antioxidant and anti-inflammatory activity.
|
In vivo | Luteolin, a flavonoid with potential for cancer prevention and therapy.[Pubmed: 18991571 ]Curr Cancer Drug Targets. 2008 Nov;8(7):634-46.Luteolin, 3',4',5,7-tetrahydroxyflavone, is a common flavonoid that exists in many types of plants including fruits, vegetables, and medicinal herbs. Plants rich in Luteolin have been used in Chinese traditional medicine for treating various diseases such as hypertension, inflammatory disorders, and cancer. Having multiple biological effects such as anti-inflammation, anti-allergy and anticancer, Luteolin functions as either an antioxidant or a pro-oxidant biochemically. The biological effects of Luteolin could be functionally related to each other. For instance, the anti-inflammatory activity may be linked to its anticancer property. Luteolin's anticancer property is associated with the induction of apoptosis, and inhibition of cell proliferation, metastasis and angiogenesis. Furthermore, Luteolin sensitizes cancer cells to therapeutic-induced cytotoxicity through suppressing cell survival pathways such as phosphatidylinositol 3'-kinase (PI3K)/Akt, nuclear factor kappa B (NF-kappaB), and X-linked inhibitor of apoptosis protein (XIAP), and stimulating apoptosis pathways including those that induce the tumor suppressor p53. These observations suggest that Luteolin could be an anticancer agent for various cancers. Furthermore, recent epidemiological studies have attributed a cancer prevention property to Luteolin.
|
Kinase Assay | Luteolin from Flos Chrysanthemi and its derivatives: New small molecule Bcl-2 protein inhibitors.[Pubmed: 25193233]Bioorg Med Chem Lett. 2014 Oct 1;24(19):4672-7.Over-expression of the Bcl-2 anti-apoptotic proteins is closely related to tumorigenesis and associated with drug resistance.
|
Cell Research | Luteolin inhibits hyperglycemia-induced proinflammatory cytokine production and its epigenetic mechanism in human monocytes.[Pubmed: 24623679]Phytother Res. 2014 Sep;28(9):1383-91.Hyperglycemia is a key feature in diabetes. Hyperglycemia has been implicated as a major contributor to several complications of diabetes. High glucose levels induce the release of proinflammatory cytokines. Luteolin is a flavone isolated from celery, green pepper, perilla leaf, and chamomile tea. Luteolin has been reported to possess antimutagenic, antitumorigenic, antioxidant, and anti-inflammatory properties. In this study, we investigated the effects of Luteolin on proinflammatory cytokine secretion and its underlying epigenetic regulation in high-glucose-induced human monocytes.
|
Animal Research | Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury.[Pubmed: 25476833 ]Life Sci. 2015 Feb 1;122:15-25.Luteolin is a falconoid compound that has an antioxidant effect, but its contribution to ROS-activated MAPK pathways in ischemia/reperfusion injury is seldom reported. Here, we have confirmed that it exhibits an antioxidant effect in myocardial ischemia/reperfusion injury (MIRI) by inhibiting ROS-activated MAPK pathways.
|
Luteolin Dilution Calculator
Luteolin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4941 mL | 17.4703 mL | 34.9406 mL | 69.8812 mL | 87.3515 mL |
5 mM | 0.6988 mL | 3.4941 mL | 6.9881 mL | 13.9762 mL | 17.4703 mL |
10 mM | 0.3494 mL | 1.747 mL | 3.4941 mL | 6.9881 mL | 8.7352 mL |
50 mM | 0.0699 mL | 0.3494 mL | 0.6988 mL | 1.3976 mL | 1.747 mL |
100 mM | 0.0349 mL | 0.1747 mL | 0.3494 mL | 0.6988 mL | 0.8735 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isosakuranin
Catalog No.:BCN3712
CAS No.:491-69-0
- Baicalein
Catalog No.:BCN5599
CAS No.:491-67-8
- Kaempferide
Catalog No.:BCN5598
CAS No.:491-54-3
- Quercetin-7-O-beta-D-glucopyranoside
Catalog No.:BCN1261
CAS No.:491-50-9
- 4-HQN
Catalog No.:BCC2448
CAS No.:491-36-1
- Valeroidine
Catalog No.:BCN1920
CAS No.:490-96-0
- Gentisic acid
Catalog No.:BCN3408
CAS No.:490-79-9
- 2,5-Dihydroxyacetophenone
Catalog No.:BCN3825
CAS No.:490-78-8
- Homoquinolinic acid
Catalog No.:BCC6570
CAS No.:490-75-5
- Gaultherin
Catalog No.:BCN2482
CAS No.:490-67-5
- Epicatechin
Catalog No.:BCN5597
CAS No.:490-46-0
- Robinetin
Catalog No.:BCN5596
CAS No.:490-31-3
- Chrysoeriol
Catalog No.:BCN5601
CAS No.:491-71-4
- Iridin
Catalog No.:BCN6868
CAS No.:491-74-7
- Biochanin A
Catalog No.:BCN1224
CAS No.:491-80-5
- Hemokinin 1 (human)
Catalog No.:BCC5923
CAS No.:491851-53-7
- TCS PIM-1 1
Catalog No.:BCC2447
CAS No.:491871-58-0
- Thermopsidine
Catalog No.:BCN7923
CAS No.:492-02-4
- (+)-Sparteine
Catalog No.:BCC9249
CAS No.:492-08-0
- Plathymenin
Catalog No.:BCN6810
CAS No.:492-12-6
- Butin
Catalog No.:BCN4630
CAS No.:492-14-8
- Kynurenic acid
Catalog No.:BCN2228
CAS No.:492-27-3
- α-D-Glucose
Catalog No.:BCC9197
CAS No.:492-62-6
- Savinin
Catalog No.:BCN5602
CAS No.:493-95-8
Luteolin from Flos Chrysanthemi and its derivatives: New small molecule Bcl-2 protein inhibitors.[Pubmed:25193233]
Bioorg Med Chem Lett. 2014 Oct 1;24(19):4672-4677.
Over-expression of the Bcl-2 anti-apoptotic proteins is closely related to tumorigenesis and associated with drug resistance. Here we report that Luteolin, a main substance found in Flos Chrysanthemi, directly binds to and shows inhibitory activity against the Bcl-2 protein. We studied the binding mode of Luteolin and its derivatives with target proteins, their structure-activity relationship, and their effect on the human leukemia cell line HL-60. The results suggest that Luteolin and its derivatives with a benzyl group introduced to the B ring, are new small molecule Bcl-2 protein inhibitors, and their anti-tumor activity is likely related to their effect on the Bcl-2 protein.
Luteolin, a flavonoid with potential for cancer prevention and therapy.[Pubmed:18991571]
Curr Cancer Drug Targets. 2008 Nov;8(7):634-46.
Luteolin, 3',4',5,7-tetrahydroxyflavone, is a common flavonoid that exists in many types of plants including fruits, vegetables, and medicinal herbs. Plants rich in Luteolin have been used in Chinese traditional medicine for treating various diseases such as hypertension, inflammatory disorders, and cancer. Having multiple biological effects such as anti-inflammation, anti-allergy and anticancer, Luteolin functions as either an antioxidant or a pro-oxidant biochemically. The biological effects of Luteolin could be functionally related to each other. For instance, the anti-inflammatory activity may be linked to its anticancer property. Luteolin's anticancer property is associated with the induction of apoptosis, and inhibition of cell proliferation, metastasis and angiogenesis. Furthermore, Luteolin sensitizes cancer cells to therapeutic-induced cytotoxicity through suppressing cell survival pathways such as phosphatidylinositol 3'-kinase (PI3K)/Akt, nuclear factor kappa B (NF-kappaB), and X-linked inhibitor of apoptosis protein (XIAP), and stimulating apoptosis pathways including those that induce the tumor suppressor p53. These observations suggest that Luteolin could be an anticancer agent for various cancers. Furthermore, recent epidemiological studies have attributed a cancer prevention property to Luteolin. In this review, we summarize the progress of recent research on Luteolin, with a particular focus on its anticancer role and molecular mechanisms underlying this property of Luteolin.
Luteolin inhibits hyperglycemia-induced proinflammatory cytokine production and its epigenetic mechanism in human monocytes.[Pubmed:24623679]
Phytother Res. 2014 Sep;28(9):1383-91.
Hyperglycemia is a key feature in diabetes. Hyperglycemia has been implicated as a major contributor to several complications of diabetes. High glucose levels induce the release of proinflammatory cytokines. Luteolin is a flavone isolated from celery, green pepper, perilla leaf, and chamomile tea. Luteolin has been reported to possess antimutagenic, antitumorigenic, antioxidant, and anti-inflammatory properties. In this study, we investigated the effects of Luteolin on proinflammatory cytokine secretion and its underlying epigenetic regulation in high-glucose-induced human monocytes. Human monocytic (THP-1) cells were cultured under controlled (14.5 mM mannitol), normoglycemic (NG, 5.5 mM glucose), or hyperglycemic (HG, 20 mM glucose) conditions, in the absence or presence of Luteolin. Luteolin (3-10 muM) was added for 48 h. While hyperglycemic conditions significantly induced histone acetylation, NF-kappaB activation, and proinflammatory cytokine (IL-6 and TNF-alpha) release from THP-1 cells, Luteolin suppressed NF-kappaB activity and cytokine release. Luteolin also significantly reduced CREB-binding protein/p300 (CBP/p300) gene expression, as well as the levels of acetylation and histone acetyltransferase (HAT) activity of the CBP/p300 protein, which is a known NF-kappaB coactivator. These results suggest that Luteolin inhibits HG-induced cytokine production in monocytes, through epigenetic changes involving NF-kappaB. We therefore suggest that Luteolin may be a potential candidate for the treatment and prevention of diabetes and its complications.
Luteolin inhibits Cr(VI)-induced malignant cell transformation of human lung epithelial cells by targeting ROS mediated multiple cell signaling pathways.[Pubmed:25448439]
Toxicol Appl Pharmacol. 2014 Dec 1;281(2):230-41.
Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated with the incidence of lung cancer. Inhibition of metal induced carcinogenesis by a dietary antioxidant is a novel approach. Luteolin, a natural dietary flavonoid found in fruits and vegetables, possesses potent antioxidant and anti-inflammatory activity. We found that short term exposure of human bronchial epithelial cells (BEAS-2B) to Cr(VI) (5muM) showed a drastic increase in ROS generation, NADPH oxidase (NOX) activation, lipid peroxidation, and glutathione depletion, which were significantly inhibited by the treatment with Luteolin in a dose dependent manner. Treatment with Luteolin decreased AP-1, HIF-1alpha, COX-2, and iNOS promoter activity induced by Cr(VI) in BEAS-2B cells. In addition, Luteolin protected BEAS-2B cells from malignant transformation induced by chronic Cr(VI) exposure. Moreover, Luteolin also inhibited the production of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8, TNF-alpha) and VEGF in chronic Cr(VI) exposed BEAS-2B cells. Western blot analysis showed that Luteolin inhibited multiple gene products linked to survival (Akt, Fak, Bcl-2, Bcl-xL), inflammation (MAPK, NF-kappaB, COX-2, STAT-3, iNOS, TNF-alpha) and angiogenesis (HIF-1alpha, VEGF, MMP-9) in chronic Cr(VI) exposed BEAS-2B cells. Nude mice injected with BEAS-2B cells chronically exposed to Cr(VI) in the presence of Luteolin showed reduced tumor incidence compared to Cr(VI) alone treated group. Overexpression of catalase (CAT) or SOD2, eliminated Cr(VI)-induced malignant transformation. Overall, our results indicate that Luteolin protects BEAS-2B cells from Cr(VI)-induced carcinogenesis by scavenging ROS and modulating multiple cell signaling mechanisms that are linked to ROS. Luteolin, therefore, serves as a potential chemopreventive agent against Cr(VI)-induced carcinogenesis.
Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury.[Pubmed:25476833]
Life Sci. 2015 Feb 1;122:15-25.
AIMS: Luteolin is a falconoid compound that has an antioxidant effect, but its contribution to ROS-activated MAPK pathways in ischemia/reperfusion injury is seldom reported. Here, we have confirmed that it exhibits an antioxidant effect in myocardial ischemia/reperfusion injury (MIRI) by inhibiting ROS-activated MAPK pathways. MAIN METHODS: We exposed rat hearts into the left anterior descending coronary artery (LAD) ligation for 30min followed by 1h of reperfusion. Observations were carried out using electrocardiography; detection of hemodynamic parameters; and testing levels of lactate dehydrogenase (LDH), creatine kinase (CK), total superoxide dismutase (T-SOD), and malondialdehyde (MDA). Mitogen-activated protein kinase (MAPK) pathway was measured by western blot and transmission electron microscopy was applied to observe the myocardial ultrastructure. Rat H9c2 cell in 95% N2 and 5% CO2 stimulated the MIRI. Oxidation system mRNA levels were measured by real-time PCR; mitochondrial membrane potential and apoptosis were measured by confocal microscopy and flow cytometry; western blot analysis was used to assay caspase-3, -8, and -9 and MAPK pathway protein expression; the MAPK pathway was inhibited using SB203580 (p38 MAPK inhibitor) and SP600125 (c-Jun NH2-terminal kinase inhibitor) before H9c2 cells were exposed to hypoxia/reoxygenation injury to show the modulation of the changes in ROS generation, cell viability and apoptosis. KEY FINDINGS: In vivo, Luteolin can ameliorate the impaired mitochondrial morphology, regulating the MAPK pathway to protect MIRI. In vitro, Luteolin can affect the oxidation system, mitochondrial membrane potential and MAPK pathway to anti-apoptosis. SIGNIFICANCE: These results reveal a ROS-MAPK mediated mechanism and mitochondrial pathway through which Luteolin can protect myocardial ischemia/reperfusion injury.
Biphasic effects of luteolin on interleukin-1beta-induced cyclooxygenase-2 expression in glioblastoma cells.[Pubmed:25409926]
Biochim Biophys Acta. 2015 Jan;1853(1):126-35.
Success in developing therapeutic approaches to target brain tumor-associated inflammation in patients has been limited. Given that the inflammatory microenvironment is a hallmark signature of solid tumor development, anti-inflammatory targeting strategies have been envisioned as preventing glioblastoma initiation or progression. Consumption of foods from plant origin is associated with reduced risk of developing cancers, a chemopreventive effect that is, in part, attributed to their high content of phytochemicals with potent anti-inflammatory properties. We explored whether Luteolin, a common flavonoid in many types of plants, may inhibit interleukin (IL)-1beta function induction of the inflammation biomarker cyclooxygenase (COX)-2. We found that IL-1beta triggered COX-2 expression in U-87 glioblastoma cells and synergized with Luteolin to potentiate or inhibit that induction in a biphasic manner. Luteolin pretreatment of cells inhibited IL-1beta-mediated phosphorylation of inhibitor of kappaB, nuclear transcription factor-kappaB (NF-kappaB) p65, extracellular signal-regulated kinase-1/2, and c-Jun amino-terminal kinase in a concentration-dependent manner. Luteolin also inhibited AKT phosphorylation and survivin expression, while it triggered both caspase-3 cleavage and expression of glucose-regulated protein 78. These effects were all potentiated by IL-1beta, in part through increased nuclear translocation of NF-kappaB p65. Finally, Luteolin was able to reduce IL-1 receptor gene expression, and treatment with IL-1 receptor antagonist or gene silencing of IL-1 receptor prevented IL-1beta/Luteolin-induced COX-2 expression. Our results document a novel adaptive cellular response to Luteolin, which triggers anti-survival and anti-inflammatory mechanisms that contribute to the chemopreventive properties of this diet-derived molecule.
Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages.[Pubmed:17977562]
Life Sci. 2007 Nov 30;81(23-24):1602-14.
Luteolin, a plant flavonoid, has potent anti-inflammatory properties both in vitro and in vivo. However, the molecular mechanism of Luteolin-mediated immune modulation has not been fully understood. In this study, we examined the effects of Luteolin on the production of nitric oxide (NO) and prostaglandin E(2) (PGE(2)), as well as the expression of inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in mouse alveolar macrophage MH-S and peripheral macrophage RAW 264.7 cells. Luteolin dose-dependently inhibited the expression and production of these inflammatory genes and mediators in macrophages stimulated with lipopolysaccharide (LPS). Semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay further confirmed the suppression of LPS-induced TNF- alpha, IL-6, iNOS and COX-2 gene expression by Luteolin at a transcriptional level. Luteolin also reduced the DNA binding activity of nuclear factor-kappa B (NF-kappaB) in LPS-activated macrophages. Moreover, Luteolin blocked the degradation of IkappaB-alpha and nuclear translocation of NF-kappaB p65 subunit. In addition, Luteolin significantly inhibited the LPS-induced DNA binding activity of activating protein-1 (AP-1). We also found that Luteolin attenuated the LPS-mediated protein kinase B (Akt) and IKK phosphorylation, as well as reactive oxygen species (ROS) production. In sum, these data suggest that, by blocking NF-kappaB and AP-1 activation, Luteolin acts to suppress the LPS-elicited inflammatory events in mouse alveolar macrophages, and this effect was mediated, at least in part, by inhibiting the generation of reactive oxygen species. Our observations suggest a possible therapeutic application of this agent for treating inflammatory disorders in lung.
A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells.[Pubmed:17296806]
Mol Pharmacol. 2007 May;71(5):1381-8.
Nuclear factor kappaB (NF-kappaB) activated by tumor necrosis factor (TNF) attenuates the TNF-induced apoptosis pathway. Therefore, blockage of NF-kappaB should improve the anticancer activity of TNF. Luteolin, a naturally occurring polyphenol flavonoid, has been reported to sensitize colorectal cancer cells to TNF-induced apoptosis through suppression of NF-kappaB; however, the mechanisms of this effect have not been well elucidated. In this article, we provide evidence showing a critical role of reactive oxygen species (ROS) accumulation induced by Luteolin in modulating TNF-activated pathways in lung cancer cells. Luteolin effectively suppressed NF-kappaB, whereas it potentiated the c-Jun N-terminal kinase (JNK) to increase apoptosis induced by TNF in lung cancer cells. Our results further demonstrate that Luteolin induced an early phase ROS accumulation via suppression of the cellular superoxide dismutase activity. It is noteworthy that suppression of ROS accumulation by ROS scavengers butylated hydroxyanisole, and N-acetyl-L-cysteine prevented the Luteolin-induced suppression of NF-kappaB and potentiation of JNK and significantly suppressed the synergistic cytotoxicity seen with cotreatment of Luteolin and TNF. Taken together, these results suggest that the accumulation of ROS induced by Luteolin plays a pivotal role in suppression of NF-kappaB and potentiation of JNK to sensitize lung cancer cells to undergo TNF-induced apoptosis.